Treatment of Unicentric Castleman Disease With Neoadjuvant Rituximab

Bandera, B; Ainsworth, Craig; Shikle, James F.; Rupard, Erik; Roach, Michael C.

doi:10.1378/chest.09-2084

Cited by 35 publications

(24 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bandera et al . [27] reported the successful use of rituximab (an anti-CD20 monoclonal antibody) in the neoadjuvant setting of mediastinal UCD involving the pulmonary artery and superior vena cava, followed by successful surgical resection. de Vries et al .…”

Section: Discussionmentioning

confidence: 99%

Retroperitoneal Castleman’s disease: advocating a multidisciplinary approach for a rare clinical entity

et al. 2014

View full text Add to dashboard Cite

BackgroundCastleman’s disease is a rare and poorly understood disease entity that may resemble more common conditions and represents a clinical challenge to the treating surgeon.Case presentationIn this report, we describe a case of a 61-year-old Caucasian woman with a symptomatic retroperitoneal mass. The specimen obtained from her resection contained a protuberant encapsulated mass, exhibiting microscopic features consistent with localized, unicentric Castleman’s disease. These characteristics included architectural features and immunohistochemical findings consistent with the hyaline vascular variant of Castleman’s disease.ConclusionWe report a very rare case of a retroperitoneal hyaline vascular type of Castleman’s disease. We discuss the diagnostic dilemma Castleman’s disease may present to the surgeon, with an emphasis on multidisciplinary management of these patients. We also review current data on pathogenesis, treatment and outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Retroperitoneal Castleman’s disease: advocating a multidisciplinary approach for a rare clinical entity

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Response to radiotherapy was reported as 72% (18). In multicentric or aggressive forms, steroids, and/ or systemic chemotherapy, and in final stages rituximab, are recommended when necessary (19). Plasma cellular CD has a worse prognosis than hyaline vascular CD and a better prognosis than HHV-8-related CD.…”

Section: Discussionmentioning

confidence: 99%

Intrathoracic Castleman disease

Biçakçioğlu¹,

Gülhan²,

Acar³

et al. 2014

Turk J Med Sci

View full text Add to dashboard Cite

Isolation and identification of Avibacterium paragallinarum, the causative agent of infectious coryza, is considered a challenging task in laboratories with limited specialties. In the present study, 14 commercial layer fowls showing the typical symptoms of infectious coryza were subjected to primary isolation followed by polymerase chain reaction confirmation of suspect colonies (culture-PCR). Direct PCR assays on infraorbital sinus swab samples were also carried out. Thirty-five suspected cases of infectious coryza in commercial broiler chickens were also screened using direct PCR on infraorbital sinus swabs. In culture-PCR, only 1 of the 4 suspected isolates was confirmed as Av. paragallinarum. In comparison, in direct PCR, 5 layer samples were shown to be positive for Av. paragallinarum. All of the broiler samples were negative in the direct PCR assay. Our findings indicate that primary isolation in combination with PCR can be a simple method for diagnosis of infectious coryza, although with a lower sensitivity than direct PCR. While direct PCR is comparably the more rapid and sensitive test, there will be instances in which the bacterial isolate is needed for further use. Hence, the culture-PCR method can be a practical and simple approach, especially in laboratories with limited specialty in identification of this fastidious organism.

show abstract

“…Radiotherapy or chemotherapy may be helpful, but it is not curative and the results vary [12]. Neoadjuvant use of rituximab [13] and neoadjuvant radiotherapy [14] have been reported in the treatment of irresectable unicentric CD to reduce tumor size and vascularity to allow for a less morbid surgical resection. In the two patients, during the intraoperative exploration, the occupation was found solitary, and the masses were encapsulated and well demarcated from the attached pancreatic tissue.…”

Section: Discussionmentioning

confidence: 99%

Castleman disease mimicked pancreatic carcinoma: report of two cases

et al. 2012

View full text Add to dashboard Cite

Castleman disease (CD) is an uncommon benign lymphoproliferative disorder, which usually presents as solitary or multiple masses in the mediastinum. Peripancreatic CD was rarely reported. Herein, we report two cases of unicentric peripancreatic CD from our center. A 43-year-old man and a 58-year-old woman were detected to have a pancreatic mass in the routine medical examinations. Both of them were asymptomatic. The computed tomography and ultrasonographic examination revealed a mild enhancing solitary mass at the pancreatic head/neck. No definite preoperative diagnosis was established and Whipple operations were originally planned. The intraoperative frozen section diagnosis of both patients revealed lymphoproliferation. Then the local excisions of mass were performed. Histological examination revealed features of CD of hyaline-vascular type. No recurrence was found during the follow-up period. CD should be included in the differential diagnosis of pancreatic tumors. Local excision is a suitable surgical choice.

show abstract

Treatment of Unicentric Castleman Disease With Neoadjuvant Rituximab

Cited by 35 publications

References 6 publications

Retroperitoneal Castleman’s disease: advocating a multidisciplinary approach for a rare clinical entity

Retroperitoneal Castleman’s disease: advocating a multidisciplinary approach for a rare clinical entity

Intrathoracic Castleman disease

Castleman disease mimicked pancreatic carcinoma: report of two cases

Contact Info

Product

Resources

About